Using nanoparticles to deliver combined chemotherapy and radiation for ovarian cancer treatment
Nanoparticle-based Intraperitoneal Delivery of Combined Chemo-radiotherapy for Treatment of Ovarian Cancer Metastases
['FUNDING_SBIR_2'] · NAMI THERAPEUTICS CORP. · NIH-10687104
This study is testing a new way to treat late-stage ovarian cancer by using tiny particles to deliver chemotherapy and radiation right where it's needed in the abdomen, aiming to help patients who have not responded well to other treatments.
Quick facts
| Phase | ['FUNDING_SBIR_2'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | NAMI THERAPEUTICS CORP. (nih funded) |
| Locations | 1 site (STORRS, UNITED STATES) |
| Trial ID | NIH-10687104 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a new treatment for late-stage ovarian cancer by using nanoparticles to deliver chemotherapy and radiation directly to the peritoneal cavity. The approach utilizes holmium-166-containing mesoporous silica nanoparticles, which are designed to target tumor tissues specifically, minimizing radiation exposure to the rest of the body. By administering this treatment directly into the abdomen, the goal is to improve patient outcomes, especially for those with chemoresistant and recurrent ovarian cancer. The research builds on previous findings that suggest intraperitoneal delivery can enhance survival rates in animal models.
Who could benefit from this research
Good fit: Ideal candidates for this research are women diagnosed with late-stage ovarian cancer, particularly those with peritoneal metastasis or who have not responded to standard treatments.
Not a fit: Patients with early-stage ovarian cancer or those whose cancer has not metastasized to the peritoneal cavity may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with advanced ovarian cancer, potentially improving survival rates and reducing side effects.
How similar studies have performed: Previous studies have shown promising results with similar nanoparticle-based therapies in animal models, indicating potential for success in human applications.
Where this research is happening
STORRS, UNITED STATES
- NAMI THERAPEUTICS CORP. — STORRS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: JAY, MICHAEL — NAMI THERAPEUTICS CORP.
- Study coordinator: JAY, MICHAEL
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Cancers, neoplasm/cancer